BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating in the health sciences and related sectors, which include businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment, or services. It also invests through equity derivatives, with an emphasis on option writing. The fund benchmarks the performance of its portfolio against the Russell 3000 Healthcare Index. BlackRock Health Sciences Trust was formed on March 31, 2005 and is domiciled in the United States.…
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
BlackRock Health Sciences Trust (NYSE: BME) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Asset Management industry, part of the Financial Services sector.
The shares were at 43.96 USD on 20 November 2026, up 17.6% over 52 weeks. Its 52-week range is 37.51 USD to 48.30 USD: the price is 9.0% below the high and 17.2% above the low.
At a market capitalisation of 568.14M USD, it trades at 5.5 times trailing earnings. The median trailing P/E of its 18 largest Asset Management peers is 14.8, a discount of 63% for BME. It pays a dividend yielding 7.08% (it pays out 39% of its earnings), against a median of 1.81% among the dividend payers in that peer group.
BlackRock Health Sciences Trust reports return on equity of 13.5%, an operating margin of 22.9% and revenue down 3.8% year over year.
Its debt exceeds its cash by 687.99K USD, a debt-to-equity ratio of 0.12. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.